

ASX Announcement



Medibio Limited – 27 October 2021

Expiry Of MEBOB Quoted Options

Melbourne, Australia and Minneapolis, MN – 27 October 2021: Medibio Limited (Medibio or the Company) (ASX: MEB) (OTCPINK: MDBIF), advises holders of 836,328,540 quoted options (ASX: MEBOB), exercisable at \$0.03 (3 cents) per option will expire at 5.00pm (AEDT) on Wednesday, 1 December 2021.

The Company advises that under ASX Listing Rule 6.24 in conjunction with Appendix 6A item 5.3, the Company does not need to send expiry notices in relation to the MEBOB quoted options as they're substantially out of the money. Accordingly, MEBOB expiry notices will not be sent to MEBOB option holders.

In accordance with 5.2 of Appendix 6A of the ASX Listing Rules, the Company provides MEBOB option holders with the following information:

- a) The total number of MEBOB options to which this notice applies is 836,328,540.
- b) On exercise, each MEBOB option entitles the holder to receive one fully paid ordinary share in the Company. If all MEBOB options were exercised, 836,328,540 fully paid ordinary shares in the Company would be issued.
- c) The exercise price for each MEBOB option is \$0.03 (3 cents).
- d) The due date for payment of the exercise price is 5.00pm (AEDT) on Wednesday, 1 December 2021.
- e) If payment is not received by 5.00pm (AEDT) on Wednesday, 1 December 2021, the MEBOB options will lapse and all rights under the MEBOB options will cease.
- f) Official quotation of the MEBOB options on ASX will cease at 5.00pm (AEDT) on Thursday, 25 November 2021, being four business days before the expiry date.
- g) The market price of the Company's shares on 26 October 2021, being the last trading day prior to the date of this Announcement, was \$0.008 (0.8 cents).
- h) The highest and lowest market price of the Company's shares during the three months preceding the date of this notice was \$0.012 (1.2 cents) and \$0.007 (0.7 cents) respectively.
- i) The exercise price of the MEBOB options is not underwritten.

If the market price of the Company's fully paid ordinary shares exceeds \$0.0225 (2.25 cents) before 3 November 2021, the Company will immediately send an option expiry notice to the MEBOB option holders.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

**About Medibio Limited**

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

For Further information:

Mathew Watkins
Company Secretary
T: +61 3 9692 7222